Get the Stockscreener App
0.9886
0.83%
0.0214
Adicet Bio Inc stock is traded at $0.9886, with a volume of 716.35K.
It is up +0.83% in the last 24 hours and up +20.37% over the past month.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
See More
Previous Close:
$0.9672
Open:
$1.04
24h Volume:
716.35K
Relative Volume:
0.74
Market Cap:
$82.30M
Revenue:
$24.99M
Net Income/Loss:
$-118.64M
P/E Ratio:
-0.7547
EPS:
-1.31
Net Cash Flow:
$-100.25M
1W Performance:
-2.48%
1M Performance:
+20.37%
6M Performance:
+81.60%
1Y Performance:
-29.84%
1-Day Range:
$0.9725
$1.0899
1-Week Range:
$0.7896
$1.0899
52-Week Range:
$0.4471
$1.54
Adicet Bio Inc Stock (ACET) Company Profile
Name
Adicet Bio Inc
Sector
Industry
Phone
617-482-2333
Address
131 DARTMOUTH STREET, BOSTON
Compare ACET with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.9885 | 148.23M | 24.99M | -118.64M | -100.25M | -1.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-24 | Resumed | Guggenheim | Buy |
| Sep-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-27-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Mar-31-22 | Initiated | SMBC Nikko | Outperform |
| Mar-08-22 | Initiated | Truist | Buy |
| Mar-04-22 | Initiated | Jefferies | Buy |
| May-18-21 | Initiated | BTIG Research | Buy |
| Apr-23-21 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Canaccord Genuity | Buy |
| Apr-08-21 | Initiated | Guggenheim | Buy |
| Nov-04-20 | Initiated | B. Riley Securities | Buy |
| Oct-27-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-16-20 | Initiated | Wedbush | Outperform |
View All
Adicet Bio Inc Stock (ACET) Latest News
Orbimed advisors buys Adicet Bio (ACET) shares worth $5 million - Investing.com India
What moving averages say about Adicet Bio Inc.2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Multi factor analysis applied to Adicet Bio Inc.July 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Adicet Bio’s SWOT analysis: cell therapy stock faces pivotal moment By Investing.com - Investing.com Australia
What RSI levels show for Adicet Bio Inc. (1IJA) stockJuly 2025 Reactions & High Conviction Investment Ideas - newser.com
Guggenheim Maintains Adicet Bio (ACET) Buy Recommendation - Nasdaq
Adicet Bio’s SWOT analysis: cell therapy stock faces pivotal moment - Investing.com India
Adicet Bio (NASDAQ:ACET) Earns Sell (E+) Rating from Weiss Ratings - MarketBeat
Adicet Bio Inc Stock Analysis and ForecastBreakout Stock Watch & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Adicet Bio stock holds steady as Citizens reiterates Market Perform - Investing.com
Adicet Bio reports positive results from ADI-001 autoimmune trial By Investing.com - Investing.com Canada
Adicet Bio Receives Nasdaq Extension for Compliance - TipRanks
Guggenheim raises Adicet Bio stock price target on positive lupus data - Investing.com
Adicet Bio Announces $80 Million Offering - citybiz
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 - Benzinga
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? - sharewise.com
Adicet Bio prices $80 million stock offering at $1 per share - Investing.com Nigeria
Adicet Bio reports positive results from ADI-001 autoimmune trial - Investing.com
Adicet Bio Announces Major Stock Offering Agreement - TipRanks
Adicet Bio Reports Promising Phase 1 Study Results - TipRanks
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - NewsBreak: Local News & Alerts
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering - The Joplin Globe
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $5.33 Consensus Target Price from Brokerages - Defense World
What analysts say about Adicet Bio Inc stockMid Cap Growth Trends & Free Explosive Portfolio Gains - earlytimes.in
Evaluating Adicet Bio Inc. with trendline analysisWeekly Trade Recap & Daily Profit Maximizing Tips - newser.com
Why Adicet Bio Inc. stock remains on buy listsMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Can Adicet Bio Inc. (1IJA) stock reach $200 price targetQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
What to expect from Adicet Bio Inc. in the next 30 days2025 Historical Comparison & AI Forecasted Entry/Exit Points - newser.com
Why Adicet Bio Inc. (1IJA) stock could rally stronglyJuly 2025 Reactions & Capital Efficient Trading Techniques - newser.com
Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is Adicet Bio Inc a good long term investmentPrice Action Trading & High Profit Trading Alerts - earlytimes.in
What momentum shifts mean for Adicet Bio Inc.July 2025 Movers & Community Verified Swing Trade Signals - newser.com
What analysts say about Adicet Bio Inc 1IJA stockPrice Volatility Patterns & Low Risk Investment Tips - earlytimes.in
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)September 30, 2025 - BioSpace
Adicet Bio Inc Stock (ACET) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):